Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472459 | 0.78 | ADRA2A (0.33) | GBA1RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL472855 | 0.78 | GAA (0.38) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL472434 | 0.74 | GBA1 (0.35) | GBA1RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL22510350 | 0.70 | GBA1 (0.40) | GBA1RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL40864 | 0.67 | KDM4E (0.46) | GBA1RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL14391718 | 0.67 | ADORA2A (0.46) | RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL22256578 | 0.65 | ADRA2A (0.34) | GBA1RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL15026758 | 0.65 | CYP2A6 (0.44) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL15947016 | 0.65 | MAPK14 (0.50) | — | |
| SCHEMBL29621110 | 0.63 | GAA (0.58) | GAAADRA2AADRA2BADRA2CPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | GBA1 1516/4885RAB9A 1734/4885NPC1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.